FIELD TRIAL OF ORAL CHOLERA VACCINES IN BANGLADESH

孟加拉国口服霍乱疫苗的现场试验

• 批准号: 3778538
• 负责人: J D CLEMENS
• 金额: --
• 依托单位: EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3778538
• 关键词: Bangladesh; Helicobacter; Vibrio cholerae; achlorhydria; child (0-11); cholera; cholera vaccine; clinical trials; communicable disease control; diarrhea; disease /disorder proneness /risk; field study; gastrointestinal infection; human subject; immunity; interview; longitudinal human study; oral administration; placebos; serology /serodiagnosis

This project entails continuing analyses of data derived from a large- scale, placebo-controlled field trial of B subunit-killed whole cell (BS- WC) and killed whole cell-only (WC) oral vaccines against cholera, conducted between 1985-90 in the Matlab field studies area of the International Center for Diarrheal Disease Research, Bangladesh. The trial enrolled ca. 89,000 subjects for study. Analyses of the first three years of follow-up revealed that each vaccine conferred ca. 50% protection against cholera episodes detected among patients seeking care at medical facilities. Additional work is ongoing to determine whether antecedent infection by Helicobacter pylori, a known cause of persistent hypochlorhydria, is a risk factor for cholera in Bangladesh. This study is evaluating serological evidence of H. pylori infection in cholera cases and community controls assembled during the field trial.

该项目需要对来自大型数据的数据进行持续分析 B 亚基灭活全细胞的规模、安慰剂对照现场试验（BS- WC）和灭活全细胞（WC）口服霍乱疫苗， 1985-90 年间在 Matlab 实地研究领域进行 国际腹泻病研究中心，孟加拉国。 这 试验注册约。 89,000 个研究对象。 前三项分析 多年的随访显示，每种疫苗都具有约。 50% 保护 预防在就医的患者中发现的霍乱疫情 设施。 正在进行额外的工作以确定先行词是否 幽门螺杆菌感染是慢性幽门螺杆菌感染的已知原因 胃酸过少是孟加拉国霍乱的危险因素。 这项研究 正在评估霍乱病例中幽门螺杆菌感染的血清学证据 以及在现场试验期间组装的社区控制。